Class II · Moderate risk
Lidocaine 1% - Sodium Bicarb 8.4% 10:1
Lack of sterility assurance.
FDA Drug Recalls
18,003 recalls, newest first
Class II · Moderate risk
Lidocaine Buffered with J-Tip 0.25 mL
Lack of sterility assurance.
Class II · Moderate risk
Alteplase 1 mg/mL 1 mL in 10 mL syringe
Lack of sterility assurance.
Class II · Moderate risk
Oxytocin 30 units in NS 500 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Norepinephrine 16 mg in NS 250 mL bag
Lack of sterility assurance.
Class II · Moderate risk
NICARdipine 25 mg in NS 250 mL EXCEL bag
Lack of sterility assurance.
Class II · Moderate risk
Magnesium Sulfate 6 GM in NS 50 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Magnesium Sulfate 4 GM in NS 50 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Magnesium Sulfate 2 GM in NS 50 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Magnesium Sulfate 1 GM in NS 50 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Labetalol 20 mg/4 mL
Lack of sterility assurance.
Class II · Moderate risk
Diltiazem 250 mg in NS 250 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Clindamycin 900 mg in NS 50 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Dexmedetomidine 400 mcg in NS 100 mL bag
Lack of sterility assurance.
Class II · Moderate risk
Amoxicillin for Oral Suspension USP
Subpotent Product: assay results for Amoxicillin were below the specification limits.
Class II · Moderate risk
Divalproex Sodium Extended-Release Tablets
cGMP deviations: Product was exposed above 50% relative humidity levels during packaging operations.
Class III · Low risk
Morphine Sulfate Extended-Release Tablets
Failed Impurities/Degradation Specifications
Class III · Low risk
Morphine Sulfate Extended-Release Tablets
Failed Impurities/Degradation Specifications
Class III · Low risk
Morphine Sulfate Extended-Release Tablets
Failed Impurities/Degradation Specifications
Class III · Low risk
Morphine Sulfate Extended-Release Tablets
Failed Impurities/Degradation Specifications
Class III · Low risk
Morphine Sulfate Extended-Release Tablets
Failed Impurities/Degradation Specifications
Class I · High risk
Aphrodisiac Platinum 40000
Marketed without an approved NDA/ANDA: FDA analysis has found the product to be tainted with sildenafil
Class II · Moderate risk
GlipiZIDE Extended-release Tablets
Failed Dissolution Specifications: dissolution failure at time zero of the repackaged lot. Drug release results were slightly above specification at time zero.
Class II · Moderate risk
TriMix MEDIUM
Lack of assurance of sterility for injectables and solutions intended to be sterile.
Class II · Moderate risk
Trimix HIGH
Lack of assurance of sterility for injectables and solutions intended to be sterile.